Genprex (NASDAQ:GNPX) Short Interest Up 69.7% in August

Genprex (NASDAQ:GNPX) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 62,590 shares, a growth of 69.7% from the July 30th total of 36,884 shares. Currently, 7.7% of the company’s shares are short sold. Based on an average daily volume of 391,029 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

GNPX has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Friday, July 17th. Wall Street Zen upgraded Genprex from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GNPX. Mayflower Financial Advisors LLC bought a new stake in shares of Genprex during the first quarter valued at approximately $36,000. Manchester Financial Inc. purchased a new position in Genprex during the first quarter valued at $36,000. Finally, Susquehanna International Group LLP lifted its position in Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the period. Institutional investors own 14.05% of the company’s stock.

Genprex Stock Down 5.1%

Shares of GNPX traded down $0.19 during trading hours on Tuesday, reaching $3.52. 31,006 shares of the company traded hands, compared to its average volume of 90,854. Genprex has a 12 month low of $3.46 and a 12 month high of $1,210.00. The company’s fifty day moving average price is $7.54 and its two-hundred day moving average price is $21.44. The company has a market capitalization of $2.89 million, a price-to-earnings ratio of -0.03 and a beta of -0.88.

Genprex (NASDAQ:GNPX) last released its quarterly earnings results on Friday, August 14th. The company reported ($9.40) earnings per share (EPS) for the quarter.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.